This blog post and the ensuing discussion present an interesting and revealing dialogue on the practicality of creating an open marketplace for biotech patents; the benefits of open-licensing must be weighed against the high capital and time requirements for vetting and development.
HGS recently completed a $225 million factory to make products that still don’t exist…
An investigation conducted by the U.S. Food and Drug Administration found a significant percentage of drugs touted as Canadian and shipped from Internet pharmacy websites claiming to be Canadian were not actually from Canada.
The California-based Scripps Research Institute has told Palm Beach County commissioners that it now prefers to build its planned biotechnology park at the Florida Atlantic campus in Jupiter, a decision that came two weeks after construction on the original site near the Everglades was halted.
With the US in regulatory limbo, Europe is winning the race to be the first regulated drugs market to approve generic copies of biotech drugs – despite the protests of the biotech pioneers who created them.
Offshoring labor to countries with cheaper labor and relaxed regulatory schemes has devastated industries such as textiles and manufacturing – and stands to do the same for much of biotechnology R&D. Read this essential series of articles to learn more about the potential and impacts of offshoring in biotechnology, and way to deal with this […]
The biotech sector saw a significant run-up last month, but for at least one analyst, questions remain about what the second half holds.
The health ministry has decided to set up an autonomous drug control authority on the lines of the US Food and Drugs Administration, but with a mandate going far beyond the latter.